AGM statement and recent progress
Destiny’s AGM included clinical and business development updates which we summarise below. In addition, there has been an increasing tempo in broader market news that helps augment Destiny’s investment proposition. These include the UK Government and GSK’s pledge on antimicrobial resistance.The group CMO also detailed the revised clinical program for XF-73 Nasal and what struck us most was the expected £25m cost. To most potential licensors of XF-73 Nasal, this level of cost (and any upfront payments) would be a ‘steal’ for a license that gets them to the other side of Phase 3, the rights to XF-73 Nasal in some jurisdictions, and a pathway to a regulatory submission.
In a recent, well-received announcement, Destiny said its product XF-73 had been awarded an IPD that provides entry into the UK’s Innovative Licensing and Access pathway (ILAP). After a similar award by the US FDA of Qualifying Infectious Disease Product (QIDP) status, this means endorsement by two transatlantic regulators, plus many tangible benefits from access to ILAP.
Our fair value for Destiny remains at £212.0m (or 234p / share) since our recent changes to reflect the longer times until Phase 3 studies start and revenues flow back. Ironically the recent IPD award may shorten some of these timelines, while QIDP status also extends exclusivity.
Destiny Pharma is engaged in the discovery, development and commercialization of antimicrobials that have properties to improve outcomes for patients and the delivery of medical care into the future.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.